Frankfurt - Delayed Quote EUR

ImmunityBio, Inc. (26CA.F)

Compare
2.7210
+0.0240
+(0.89%)
As of 8:05:02 AM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 26CA.F

Recent News: 26CA.F

View More
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
Business Wire 19 hours ago
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
Business Wire 4 days ago
Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz
TipRanks 11 days ago
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
Business Wire 12 days ago
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Business Wire 18 days ago
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
Business Wire last month
Exploring High Growth Tech Stocks in the United States

Exploring High Growth Tech Stocks in the United States
Simply Wall St. last month
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Business Wire last month
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
Business Wire last month
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
Business Wire last month
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
Business Wire last month
View More

Related Tickers

CRO.BE Open Orphan PLC
0.1990
0.00%
 
6XY.F HBM Holdings Limited
0.6450
0.00%
 
8JD.F Valbiotis SA
1.2680
-0.63%
 
OPORF hVIVO plc
0.2400
-31.43%
 
CRO.F hVIVO plc
0.1740
0.00%
 
HPHA.F Heidelberg Pharma AG
2.5600
-2.66%
 
8C5.F Coherus BioSciences, Inc.
0.9456
-7.25%
 
GBM.F Inovio Pharmaceuticals, Inc.
1.7500
-6.91%
 
2LB.F Iovance Biotherapeutics, Inc.
3.8200
-1.32%
 
VICO.ST Vicore Pharma Holding AB (publ)
7.89
-0.38%